New anticoagulants: Moving beyond the direct oral anticoagulants

  title={New anticoagulants: Moving beyond the direct oral anticoagulants},
  author={James C Fredenburgh and Jeffrey I. Weitz},
  journal={Journal of Thrombosis and Haemostasis},
  pages={20 - 29}
Although anticoagulants have been in use for more than 80 years, heparin and vitamin K antagonists were the sole available options until recently. Although these agents revolutionized the prevention and treatment of thrombotic diseases, their use has been hampered by the necessity for coagulation monitoring and by bleeding complications resulting in part from their multiple sites of action. Owing to advances in basic science, animal models, and epidemiology, the arsenal of available… Expand
8 Citations
Eighty years of oral anticoagulation: Learning from history.
This review highlights the evolution of oral anticoagulant therapy tracing the key stages of a long and fascinating history that has unfolded from the first part of the twentieth century until today, indeed an intriguing journey where serendipity is intertwined with the tenacious work of many researchers. Expand
Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation
The most recent evidence about antithrombotic therapy in PAD patients is highlighted, with a special focus on oral anticoagulation, and rivaroxaban in combination with aspirin seem to reduce cardiovascular outcomes with a similar bleeding risk compared to aspirin alone. Expand
Aprotinin Inhibits Thrombin Generation by Inhibition of the Intrinsic Pathway, but is not a Direct Thrombin Inhibitor
The anticoagulant properties of aprotinin may be beneficial during surgical procedures in which pathological activation of the intrinsic pathway, for example by extracorporeal circuits, occurs. Expand
Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant
AAT-RC-2 is the most selective and active AAT variant reported to date for FXIa inhibition and will be tested in animal models of thrombosis and bleeding and Structural modeling of the AAT- RC-2/FXIa encounter complex suggested that both E (Glu) substitutions at P3 and P3' may promote FXIi binding via hydrogen bonding to K192 in FXia. Expand
Evolution of Clinical Thinking and Practice Regarding Aspirin: What Has Changed and Why?
An overview of the important questions surrounding a more informed approach to ASA therapy: duration of therapy, assessment of net clinical benefit, and timing of start and stop strategies is presented. Expand
Management of Disseminated Intravascular Coagulation in Acute Leukemias.
The cornerstone of managing DIC is the treatment of the underlying disease, as exemplified by the important role of early administration of all-trans retinoic acid in APL, and other aspects of management focus on supportive care aimed at minimizing the risk of bleeding, via transfusion of blood products. Expand
Thrombosis: Grand Challenges Ahead!
  • H. ten Cate
  • Medicine
  • Frontiers in Cardiovascular Medicine
  • 2021
Thrombosis is the immediate trigger of a number of acute cardiovascular diseases, including myocardial infarction, ischemic stroke, and venous thromboembolism (VTE), which are all leading causes of mortality and long-termmorbidity, affecting men and women of all ethnicities all over the world. Expand


Factors XI and XII as Targets for New Anticoagulants
This review highlights the evidence for focusing on FXI and FXII and examines the novel approaches directed at these new targets of anticoagulant therapy by reducing the risk of bleeding. Expand
From multi-target anticoagulants to DOACs, and intrinsic coagulation factor inhibitors.
Developed in the early 21st century, DOACs have comparable efficacy to LMWHs, but increase bleeding risk, as the anticoagulant targets (FIIa, FXa) are also essential for physiological hemostasis, and the revision of coagulation models over time is reviewed. Expand
New developments in anticoagulants: Past, present and future.
Low-molecular-weight heparin and fondaparinux have replaced UFH for prevention and initial treatment of venous thromboembolism and for secondary prevention in cancer patients and how specific reversal agents for the NOACs will enhance their safety is outlined. Expand
Plasma contact factors as therapeutic targets.
The biochemistry of contact activation, the contributions of contact factors in thrombosis, and novel antithrombotic agents targeting contact factors that are undergoing pre-clinical and early clinical testing are discussed. Expand
Current and Emerging Direct Oral Anticoagulants: State-of-the-Art.
It is shown that DOACs sharing very similar mechanisms of action are still characterized by different efficacy and safety profiles, which contributes to challenging the minds of physicians, who may find difficulty navigating their way through multiple indications, different pharmacological profiles, various side effects, and specific drug-to-drug interactions. Expand
Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants.
The pharmacology of the direct oral anticoagulants is reviewed and the advantages of the DOACs over vitamin K antagonists are described, as well as highlighting current challenges and limitations, and identifying future directions for antICOagulant therapy. Expand
The role of structural information in the discovery of direct thrombin and factor Xa inhibitors.
  • H. Nar
  • Medicine
  • Trends in pharmacological sciences
  • 2012
This review uses selected case studies to describe the discovery of novel fIIa and fXa inhibitors, with a particular emphasis on the pre-eminent role that structural information played in this process. Expand
Therapeutic strategies for thrombosis: new targets and approaches
An overview of haemostasis and thrombosis is provided, the current landscape of antithrombotic agents is detailed, challenges with preventing thromboembolic events in patients at high risk are addressed, and the emerging therapeutic strategies that may break the inexorable link between antithROMbotic therapy and bleeding risk are described. Expand
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism
In the acute treatment of VTE, DOACs were non-inferior and probably safer than conventional anticoagulation therapy while in the extended VTE treatment DOACS were more effective than placebo or aspirin with a comparable risk of major bleeding. Expand
MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans.
A first-in-human study in healthy subjects showed that single subcutaneous doses of MAA868 were safe and well tolerated, and resulted in dose- and time-dependent robust and sustained prolongation of activated partial thromboplastin time and FXI suppression for up to 4 weeks or longer, supporting further clinical investigation as a potential once-monthly sub cutaneous anticoagulant therapy. Expand